John F. DiJoseph

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

John F. DiJoseph, Douglas Armellino, Erwin R. Boghaert et al. · Blood · 2003 · 354 citations · Full text

A general approach to site-specific antibody drug conjugates

Feng Tian, Yingchun Lu, Anthony Manibusan et al. · Proceedings of the National Academy of Sciences · 2014 · 309 citations · Full text

Medicinal Chemistry, Biochemistry, Polymer-drug Conjugate +15

Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma

John F. DiJoseph, Maureen Dougher, Lyka B. Kalyandrug et al. · Clinical Cancer Research · 2006 · 140 citations · Full text

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

John F. DiJoseph, Maureen Dougher, Douglas Armellino et al. · Leukemia · 2007 · 134 citations

Inotuzumab Ozogamicin, Lymphoid Neoplasia, Hematological Malignancy +9

THE EFFECT OF RAPAMYCIN ON KIDNEY FUNCTION IN THE SPRAGUE-DAWLEY RAT

John F. DiJoseph, R. N. SHARMA, Jennifer Y. Chang · Transplantation · 1992 · 100 citations

Urology, Renal Function, Medicine +14